Osteoblast CFTR inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Stalvey, Michael S ^a   Clines, Katrina L ^b   Havasi, Viktoria ^a   McKibbin, Christopher R ^c   Dunn, Lauren K ^c   Chung, W Joon ^d   Clines, Gregory A ^b,e  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d University of Alabama at Birmingham   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; WNT PROTEIN; WNT3A PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE MASS; CALVARIA; CELL COUNT; CELL DIFFERENTIATION; CFTR GENE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME REPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INACTIVATION; IN VITRO STUDY; MOUSE; NONHUMAN; OPG GENE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; RANKL GENE; WNT SIGNALING PATHWAY;

ANIMALS; BONE DISEASES; BONE RESORPTION; CELL DIFFERENTIATION; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DISEASE MODELS, ANIMAL; FEMALE; FRACTURES, BONE; GENE EXPRESSION; MICE; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PARATHYROID HORMONE; WNT SIGNALING PATHWAY;

EID: 84893370295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080098     Document Type: Article

References (46)

1. Mischler EH, Chesney PJ, Chesney RW, Mazess RB (1979) Demineralization in cystic fibrosis detected by direct photon absorptiometry. American Journal of Diseases of Children 133: 632-635. (Pubitemid 9212667)
2. Hahn TJ, Squires AE, Halstead LR, Strominger DB (1979) Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis. Journal of Pediatrics 94: 38-42. (Pubitemid 9036125)
3. Aris RM, Renner JB, Winders AD, Buell HE, Riggs DB, et al. (1998) Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Annals of Internal Medicine 128: 186-193. (Pubitemid 28078199)
4. Shapiro BJ, Veeraraghavan S, Barbers RG (1999) Lung transplantation for cystic fibrosis: an update and practical considerations for referring candidates. Current Opinion in Pulmonary Medicine 5: 365-370.
5. Baroncelli GI, De Luca F, Magazzu G, Arrigo T, Sferlazzas C, et al. (1997) Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatric Research 41: 397-403. (Pubitemid 27097909)
6. Elkin SL, Fairney A, Burnett S, Kemp M, Kyd P, et al. (2001) Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporosis International 12: 366-372. (Pubitemid 32606460)
7. Aris RM, Ontjes DA, Buell HE, Blackwood AD, Lark RK, et al. (2002) Abnormal bone turnover in cystic fibrosis adults. Osteoporosis International 13: 151-157. (Pubitemid 34245373)
8. Dif F, Marty C, Baudoin C, de Vernejoul MC, Levi G (2004) Severe osteopenia in CFTR-null mice. Bone 35: 595-603. (Pubitemid 39144418)
9. Haston CK, Li W, Li A, Lafleur M, Henderson JE (2008) Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. American Journal of Respiratory & Critical Care Medicine 177: 309-315. (Pubitemid 351198374)
10. King SJ, Topliss DJ, Kotsimbos T, Nyulasi IB, Bailey M, et al. (2005) Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. European Respiratory Journal 25: 54-61. (Pubitemid 40207731)
11. Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, et al. (2005) Guide to bone health and disease in cystic fibrosis. Journal of Clinical Endocrinology & Metabolism 90: 1888-1896. (Pubitemid 40464064)
12. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, et al. (1992) An animal model for cystic fibrosis made by gene targeting. Science 257: 1083-1088.
13. Snouwaert JN, Brigman KK, Latour AM, Iraj E, Schwab U, et al. (1995) A murine model of cystic fibrosis. Amô Jô Respir Crit Care Med 151: S59-64.
14. Clarke LL, Grubb BR, Yankaskas JR, Cotton CU, McKenzie A, et al. (1994) Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. Proc Natl Acad Sciô Uô Sô A 91: 479-483.
15. Kent G, Iles R, Bear CE, Huan LJ, Griesenbach U, et al. (1997) Lung disease in mice with cystic fibrosis. Jô Clin Invest 100: 3060-3069. (Pubitemid 28022844)
16. Le Henaff C, Gimenez A, Hay E, Marty C, Marie P, et al. (2012) The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation. Amô Jô Pathol 180: 2068-2075.
17. Pashuck TD, Franz SE, Altman MK, Wasserfall CH, Atkinson MA, et al. (2009) Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation. Pediatr Res 65: 311-316.
18. Koller BH, Kim HS, Latour AM, Brigman K, Boucher RC Jr, et al. (1991) Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America 88: 10730-10734. (Pubitemid 21915911)
19. Hodges CA, Cotton CU, Palmert MR, Drumm ML (2008) Generation of a conditional null allele for Cftr in mice. Genesis 46: 546-552.
20. Clines GA, Mohammad KS, Bao Y, Stephens O, Suva LJ, et al. (2007) Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Molecular Endocrinology 22: 486-498. (Pubitemid 46184897)
21. Mohammad KS, Chirgwin JM, Guise TA (2008) Assessing new bone formation in neonatal calvarial organ cultures. Methods in Molecular Biology 455: 37-50.
22. Bakker A, Klein-Nulend J (2003) Osteoblast isolation from murine calvariae and long bones. In: Helfrich MH, Ralston SH, editors. Bone research protocols. Totowa, New Jersey: Humana Press. pp. 19-28.
23. Bronckers A, Kalogeraki L, Jorna HJ, Wilke M, Bervoets TJ, et al. (2010) The cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in maturation stage ameloblasts, odontoblasts and bone cells. Bone 46: 1188-1196.
24. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319. (Pubitemid 27199902)
25. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, et al. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337. (Pubitemid 28510154)
26. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176. (Pubitemid 28180851)
27. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179. (Pubitemid 27507987)
28. Fu Q, Jilka RL, Manolagas SC, O'Brien CA (2002) Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. Journal of Biological Chemistry 277: 48868-48875. (Pubitemid 35470855)
29. Kondo H, Guo J, Bringhurst FR (2002) Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. Journal of Bone & Mineral Research 17: 1667-1679.
30. Baron R, Rawadi G (2007) Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 148: 2635-2643. (Pubitemid 46984775)
31. Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, et al. (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8: 751-764. (Pubitemid 40585297)
32. Foundation CF (2011) Patient Registry: Annual Data Report 2011. Bethesda, Maryland.
33. Liang H, Yang L, Ma T, Zhao Y (2010) Functional expression of cystic fibrosis transmembrane conductance regulator in mouse chondrocytes. Clin Exp Pharmacol Physiol 37: 506-508.
34. Lamhonwah AM, Bear CE, Huan LJ, Kim Chiaw P, Ackerley CA, et al. (2010) Cystic fibrosis transmembrane conductance regulator in human muscle: Dysfunction causes abnormal metabolic recovery in exercise. Ann Neurol 67: 802-808.
35. Divangahi M, Balghi H, Danialou G, Comtois AS, Demoule A, et al. (2009) Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet 5: e1000586.
36. Di A, Brown ME, Deriy LV, Li C, Szeto FL, et al. (2006) CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 8: 933-944. (Pubitemid 44314724)
37. Naren AP, Cobb B, Li C, Roy K, Nelson D, et al. (2003) A macromolecular complex of beta 2 adrenergic receptor, CFTR, and ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. Proceedings of the National Academy of Sciences of the United States of America 100: 342-346. (Pubitemid 36078076)
38. Pietrement C, Da Silva N, Silberstein C, James M, Marsolais M, et al. (2008) Role of NHERF1, cystic fibrosis transmembrane conductance regulator, and cAMP in the regulation of aquaporin 9. Jô Biol Chem 283: 2986-2996.
39. Wang B, Bisello A, Yang Y, Romero GG, Friedman PA (2007) NHERF1 regulates parathyroid hormone receptor membrane retention without affecting recycling. Journal of Biological Chemistry 282: 36214-36222.
40. Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, et al. (2007) Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 62: 650-651. (Pubitemid 47056896)
41. Shead EF, Haworth CS, Barker H, Bilton D, Compston JE (2010) Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. Jô Cyst Fibros 9: 93-98.
42. Le Heron L, Guillaume C, Velard F, Braux J, Touqui L, et al. (2010) Cystic fibrosis transmembrane conductance regulator (CFTR) regulates the production of osteoprotegerin (OPG) and prostaglandin (PG) E2 in human bone. Jô Cyst Fibros 9: 69-72.
43. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, et al. (2005) Essential role of beta-catenin in postnatal bone acquisition. Journal of Biological Chemistry 280: 21162-21168. (Pubitemid 40805677)
44. Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K, et al. (2008) PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. Jô Cell Biochem 104: 304-317.
45. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, et al. (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 112: 196-207.
46. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, et al. (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New England Journal of Medicine 349: 1207-1215. (Pubitemid 37152030)